<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288000</url>
  </required_header>
  <id_info>
    <org_study_id>2012_55</org_study_id>
    <secondary_id>2013-001671-21</secondary_id>
    <nct_id>NCT02288000</nct_id>
  </id_info>
  <brief_title>Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases</brief_title>
  <acronym>WP3_P002</acronym>
  <official_title>Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The early assessment of new drugs for Alzheimer's disease remains difficult because of the
      lack of predictive end-point. The use of a battery including different parameters could
      improve this early development of new drugs. Nevertheless, the interest of such a battery
      should previously be validated with the yet marketed AD drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study is to test the effect of a 15-day treatment with memantine on a
      mixed battery associating cognitive assessment, imaging and neurophysiological tests in
      healthy volunteers.

      This multicenter, randomized, placebo-controlled, cross-over study is double-blind controlled
      and is conducted in 3 centers located in France (Lille, Marseille and Toulouse).

      18-30 years old, healthy volunteers, without any neurological or psychiatric impairment, will
      complete 2 test sessions in a randomized order: one with a 15-day treatment with memantine,
      the other with placebo, and will be submitted to a mixed battery during the 14th and 15th day
      of the treatment. The primary outcome of the study will be based on cognitive assessment,
      imaging parameters and neurophysiological parameters
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacog battery</measure>
    <time_frame>15 days</time_frame>
    <description>cognitive tests (8 items of the Cantab battery) :
Motor screening
4 tests for visual memory (Delayed Matching to Sample, Paired Associated Learning, Pattern Recognition Memory, Spatial Recognition Memory)
1 test for executive functions (Spatial Working Memory)
2 tests for attention (Reaction Time, Rapid Visual Information Processing)
completed by a modified ADNI battery : ADAScog
imaging
fMRI
PET-FDG
neurophysiological
EEG</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Battery</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Memantine will be administered OS as of 10 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will be presented as tablet comparable to Ebixa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Memantine will be administered OS as of 10 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.</description>
    <arm_group_label>Memantine</arm_group_label>
    <other_name>EBIXA ® Memantine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>the placebo will be administered OS as of 10 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-30 year old male non-smoker subjects

          -  Subject without cognitive impairment or cognitive complaint (Moca&gt;26, Mac Nair
             scale&lt;15)

          -  Subject without history of brain disease (severe brain trauma, stroke, cerebral
             tumor,…)

          -  Subject without major medical or surgical history

          -  Subject without current chronic disease

          -  Subject without current cerebral disease

          -  Subject without vascular or metabolic risk factor

          -  Subject without history or current mental disease or addiction (MINI)

          -  Subject without lesion on MRI

          -  Subject without abnormal electrical activities on EEG

          -  Subject without use of chronic treatment or psychotropic drugs or substances

          -  French speaker subject and able to understand the test instructions

        Exclusion Criteria:

          -  Subject with dementia or cognitive decline identified by Moca &lt; 26

          -  Subject with vascular or metabolic risk factor

          -  Subject with history or current mental disease or addiction

          -  Subject with family history of young-onset dementia

          -  Subject with family history of chronic or severe neurological or mental disease (first
             degree relatives)

          -  Subject receiving a chronic treatment

          -  Subject with claustrophobia or contra-indication to MRI

          -  Subject unable to understand the test instructions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Régis Bordet, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Régis Bordet, MD, PhD</last_name>
    <phone>+33 (0)3 20 44 54 49</phone>
    <phone_ext>+33</phone_ext>
    <email>regis.bordet@univ-lille2.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Lille/ Centre d'investigation Clinique</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Deplanque, PH</last_name>
      <email>dominique.deplanque@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Régis Bordet, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIC Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Blin</last_name>
      <email>olivier.blin@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIC Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Rascol</last_name>
      <email>cic9302@purpan.inserm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>Memantine</keyword>
  <keyword>biomarkers</keyword>
  <keyword>battery</keyword>
  <keyword>cognition</keyword>
  <keyword>imaging</keyword>
  <keyword>neuropsychology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

